Foresite Capital
900 Larkspur Landing CircleLarkspur, CA 94939
Website: foresitecapital.com
Firm Size
- Assets Under Management (AUM):$3.5 Billion
- Number of Funds:9
- Employees:54
- Firm Type:Venture Capital
- Focus Areas:
Software & Technology
Healthcare
Description
Foresite Capital is a venture capital firm based in Larkspur, California. The company primarily invests in the healthcare industry, specializing in biotechnology, medical devices, diagnostics, and digital health sectors. Foresite Capital focuses on providing capital and strategic guidance to emerging healthcare companies with innovative technologies and promising growth potential. The firm's team consists of experienced professionals with backgrounds in finance, healthcare, and technology. Foresite Capital aims to support and facilitate the development of groundbreaking advances in healthcare, improving patient outcomes and transforming the industry.Latest News
Powered by
Feb 14, 2024: Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines
Latigo Biotherapeutics Inc. ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain medicines that target pain at its source, today announced its emergence from stealth with a $135 million Series A financing. Westlake Village BioPartners ("Westlake") incubated the company. Westlake led the Series A financing with 5AM Ventures and Foresite Capital as co-leads with participation from Corner Ventures.
Jan 03, 2024: Remix Therapeutics Closes $60 Million Financing to Advance REM-422, Pipeline of Small Molecule Therapies Designed to Reprogram RNA Processing to Treat Disease
Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced the close of a $60 million financing led by The Column Group. The financing includes participation from existing investors Atlas Venture, Foresite Capital, Alexandria Venture Investments, Arch Venture Partners, Casdin Capital, and Surveyor (a Citadel company) along with new investors WTT Investment, Willett Advisors, and others. The funds will support clinical development of the company's lead program, REM-422, and further advancement of a pipeline of RNA processing targeted therapeutics.
Nov 27, 2023: Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLC
On November 22, 2023 , the board of directors (the Board) of Theseus Pharmaceuticals, Inc. (NASDAQ: THRX) (Theseus or the Company) received an unsolicited joint letter from funds and persons affiliated with Foresite Capital, LLC (collectively, Foresite) and funds and persons affiliated with OrbiMed Advisors LLC (collectively, OrbiMed), in which Foresite and OrbiMed indicated their intent to explore and evaluate a potential acquisition of all of the outstanding shares of common stock of the Company not already owned by Foresite or OrbiMed in a going-private transaction.
Aug 22, 2023: Thyme Care Secures $60M Series B to Scale Cancer Care Beyond the Clinic
Apr 27, 2023: Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform
Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced today that it has closed an oversubscribed Series B financing round of $58.75 million . The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University , and The University of Colorado Healthcare Innovation Fund. The proceeds will be used to accelerate the clinical development and commercialization of Foresight Diagnostics' cancer recurrence testing platform, PhasED-Seq™.